Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial.

Corbevax (BECOV2D) - Biological E Ltd

http://www.ncbi.nlm.nih.gov/pubmed/40746973

A Venkateshwar Rao; Chandrashekhar S Gillurkar; Chirag Dhar; Mallikarjuna Panchakshari; Manish Narang; Rammohan Reddy Mogulla; Shivnitwar Sachin Kisan; Siddalingaiah Ningaiah; SubbaReddy Gunneri; Subhash Thuluva; Vijay Yerroju; Vikram Paradkar

Aug 1, 2025